Iambic Therapeutics Filed IND for Novel Cancer Drug
The San Diego biotech aims to initiate human trials for its AI-designed brain-penetrant KIF18A inhibitor.
Live Poll
Will AI-driven platforms significantly shorten the development time for new cancer medications?